Triple negative breast cancer (TNBC) represent approximately 10% of BCs and is defined as tumors lacking estrogen receptor (ER), progesterone receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) expression (ER−, PR−, HER2−). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.